Security
INTI · Inhibitor Therapeutics, Inc.
INTIOTCCommon stockCurrentCIK 1042418Updated Sep 25, 2026
Name history
HedgePath Pharmaceuticals, Inc. · through Aug 12, 2019COMMONWEALTH BIOTECHNOLOGIES INC · through May 20, 2013
INTI price & chart
Loading TradingView…
OTC:INTI on TradingView ↗In the news
Inhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin Syndrome ↗
Recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.07
DEF 14A filing
10-Q filing
4 filing
10-Q filing
Show 5 more recent filings
Regulation FD Disclosure
Items 7.01, 9.01
Other Events
Items 8.01, 9.01
10-K filing
Entry into a Material Definitive Agreement
Items 1.01, 9.01
10-Q filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 2,511,307Source | 5,694,658Source | 8,949,155Source | 11,975,124Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 2,375,493Source | 5,606,863Source | 8,839,912Source | 11,951,224Source |
| Assets, CurrentUSD | 2,447,000Source | 5,694,658Source | 8,949,155Source | 11,975,124Source |
| Prepaid Expense and Other Assets, CurrentUSD | 71,507Source | 87,795Source | 109,243Source | — |
| Operating Lease, Right-of-Use AssetUSD | 64,307Source | — | — | — |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 3,803,219Source | 3,709,618Source | 3,665,164Source | 3,678,782Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 17,257Source | 17,232Source | 17,202Source | 17,179Source |
| Additional Paid in CapitalUSD | 54,110,425Source | 54,087,065Source | 54,046,845Source | — |
| Retained Earnings (Accumulated Deficit)USD | -55,419,594Source | -52,119,257Source | -48,780,056Source | -45,753,921Source |
| Stockholders' Equity Attributable to ParentUSD | -1,291,912Source | 1,985,040Source | 5,283,991Source | 8,296,342Source |
| Additional Paid in Capital, Common StockUSD | — | — | — | 54,033,084Source |
| Liabilities and EquityUSD | 2,511,307Source | 5,694,658Source | 8,949,155Source | 11,975,124Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 766,330Source | 709,618Source | 665,164Source | 678,782Source |
| Accounts Payable, CurrentUSD | 51,521Source | 15,896Source | 33,731Source | 145,161Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 690,085Source | 693,722Source | 631,433Source | 122,621Source |
| Deferred Revenue, NoncurrentUSD | 3,000,000Source | 3,000,000Source | 3,000,000Source | 3,000,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | 55,000Source | 55,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 23,385Source | 40,250Source | 13,784Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -3,231,370Source | -3,233,049Source | -2,700,312Source | 11,740,598Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | -411,000Source | 180,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -3,231,370Source | -3,233,049Source | -3,111,312Source | 11,920,598Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 2,375,493Source | 5,606,863Source | 8,839,912Source | 11,951,224Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | — | — | 53,088Source | — |
| Additional Financial Items | ||||
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | 12,619,492Source |
| General and Administrative ExpenseUSD | 1,729,935Source | 1,974,859Source | 2,023,913Source | 651,776Source |
| Income Tax Expense (Benefit)USD | — | — | — | 55,109Source |
| Net Income (Loss) Attributable to ParentUSD | -3,300,337Source | -3,339,201Source | -3,026,135Source | 12,106,230Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -3,026,135Source | 11,917,188Source |
| Operating ExpensesUSD | 3,426,653Source | 3,657,409Source | 3,404,979Source | 657,926Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -3,426,653Source | -3,657,409Source | -3,404,979Source | -657,926Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -3,026,135Source | 12,161,339Source |
| Income Tax Expense (Benefit)USD | — | — | — | 55,109Source |
| Net Income (Loss) Attributable to ParentUSD | -3,300,337Source | -3,339,201Source | -3,026,135Source | 12,106,230Source |
| Earnings Per Share, BasicUSD per share | -0.02Source | -0.02Source | -0.02Source | 0.03Source |
| Earnings Per Share, DilutedUSD per share | -0.02Source | -0.02Source | -0.02Source | 0.03Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 172,511,901Source | 172,262,889Source | 171,950,108Source | 366,183,697Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 172,511,901Source | 172,262,889Source | 171,950,108Source | 367,776,961Source |
| Additional Financial Items | ||||
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | 12,619,492Source |
| General and Administrative ExpenseUSD | 1,729,935Source | 1,974,859Source | 2,023,913Source | 651,776Source |
| Interest and Other IncomeUSD | 126,316Source | 318,208Source | 378,844Source | — |
| Interest ExpenseUSD | — | — | — | 23,234Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -3,026,135Source | 11,917,188Source |
| Operating ExpensesUSD | 3,426,653Source | 3,657,409Source | 3,404,979Source | 657,926Source |
| Preferred Stock Dividends, Income Statement ImpactUSD | — | — | — | 189,042Source |
| Research and Development ExpenseUSD | 1,696,718Source | 1,682,550Source | 1,381,066Source | 6,150Source |
Filing attachments
ex99-1.htm · 8-K · 2026-04-01
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Inhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin Syndrome Company outlines near-term pharmacokinetic milestones, highlights amorphous formulation strategy, and announces planned global patent filing TAMPA, Fla., March 31, 2026 - Inhibitor Therapeutics, Inc. (OTCQB: INTI) (“Inhibitor” or the “Company”), today provided an update on its ongoing pharmacokinetic (PK) clinical program supporting the …
Read attachment ↗ex4-1.htm · 8-K · 2026-02-24
EX-4.1 2 ex4-1.htm EX-4.1 Exhibit 4.1 EXECUTION VERSION THE WARRANT REPRESENTED BY THIS CERTIFICATE AND THE SHARES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY STATE SECURITIES LAWS AND NEITHER SUCH SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES…
Read attachment ↗